Modulation of the Innate Response to AAV Gene Therapy Vectors

Time: 11:00 am
day: Day Two


  • Since potentially immune-related toxicities have been observed in AAV gene therapy trials, there is a need for identification of efficacious immunomodulatory
  • We describe innate immune responses to AAV and identify the key role of preexisting antibodies, complement and IL-6 signalling pathways
  • Short-term inhibition of the early innate responses at the time of vector administration may be a promising approach lowering the immunogenicity of AAV vectors